126 related articles for article (PubMed ID: 23906303)
1. The predictive value of semaphorins 3 expression in biopsies for biochemical recurrence of patients with low- and intermediate-risk prostate cancer.
Li K; Chen MK; Li LY; Lu MH; Shao ChK; Su ZL; He D; Pang J; Gao X
Neoplasma; 2013; 60(6):683-9. PubMed ID: 23906303
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
3. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
5. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
6. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage.
Thomas GV; Schrage MI; Rosenfelt L; Kim JH; Salur G; deKernion JB; Dorey F; Said J; Reiter RE
J Urol; 2000 Dec; 164(6):1987-91. PubMed ID: 11061897
[TBL] [Abstract][Full Text] [Related]
7. Prediction of biochemical recurrence after radical prostatectomy using peritumoral lymphatic vessel density in biopsy specimens in patients with localized prostate cancer.
Kuroda K; Horiguchi A; Asano T; Tasaki S; Yoshii H; Sato A; Asakuma J; Ito K; Seguchi K; Sumitomo M; Asano T
Urol Int; 2012; 88(1):18-24. PubMed ID: 22222198
[TBL] [Abstract][Full Text] [Related]
8. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Miyake H; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Urol Oncol; 2010; 28(2):145-51. PubMed ID: 18848789
[TBL] [Abstract][Full Text] [Related]
9. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy.
Freedland SJ; deGregorio F; Sacoolidge JC; Elshimali YI; Csathy GS; Dorey F; Reiter RE; Aronson WJ
J Urol; 2003 Apr; 169(4):1325-30. PubMed ID: 12629353
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
[TBL] [Abstract][Full Text] [Related]
11. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
[TBL] [Abstract][Full Text] [Related]
12. Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database.
Abern MR; Aronson WJ; Terris MK; Kane CJ; Presti JC; Amling CL; Freedland SJ
Prostate; 2013 Mar; 73(4):409-17. PubMed ID: 22996686
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancers of different zonal origin: clinicopathological characteristics and biochemical outcome after radical prostatectomy.
Iremashvili V; Pelaez L; Jordá M; Manoharan M; Rosenberg DL; Soloway MS
Urology; 2012 Nov; 80(5):1063-9. PubMed ID: 23107397
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy.
Behnsawy HM; Miyake H; Harada K; Fujisawa M
BJU Int; 2013 Jan; 111(1):30-7. PubMed ID: 23107154
[TBL] [Abstract][Full Text] [Related]
15. Comparison of prostate cancer tumor volume and percent cancer in prediction of biochemical recurrence and cancer specific survival.
Chung BI; Tarin TV; Ferrari M; Brooks JD
Urol Oncol; 2011; 29(3):314-8. PubMed ID: 19837617
[TBL] [Abstract][Full Text] [Related]
16. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.
Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A
BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
18. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
19. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.
Shikanov S; Song J; Royce C; Al-Ahmadie H; Zorn K; Steinberg G; Zagaja G; Shalhav A; Eggener S
J Urol; 2009 Jul; 182(1):139-44. PubMed ID: 19450829
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
